References
- Lindeboom JA, Bruijnesteijn van Coppenraet LE, van Soolingen D, et al. Clinical manifestations, diagnosis, and treatment of Mycobacterium haemophilum infections. Clin Microbiol Rev. 2011;24(4):701–717.
- Lindeboom JA, Prins JM, Bruijnesteijn van Coppenraet ES, et al. Cervicofacial lymphadenitis in children caused by Mycobacterium haemophilum. Clin Infect Dis. 2005;41(11):1569–1575.
- Shah MK, Sebti A, Kiehn TE, et al. Mycobacterium haemophilum in immunocompromised patients. Clin Infect Dis. 2001;33(3):330–337.
- Lott JP, Werth VP, Kovarik CL. Cutaneous Mycobacterium haemophilum infection in iatrogenically immunocompromised patients without transplantation. J Am Acad Dermatol. 2008;59(1):139–142.
- Copeland NK, Arora NS, Ferguson TM. Mycobacterium haemophilum masquerading as leprosy in a renal transplant patient. Case Rep Dermatol Med. 2013;2013:793127.
- Simner PJ, Doerr KA, Steinmetz LK, et al. Mycobacterium and aerobic actinomycete culture: are two medium types and extended incubation times necessary? J Clin Microbiol. 2016;54(4):1089–1093.
- Buckwalter SP, Olson SL, Connelly BJ, et al. Evaluation of Matrix-Assisted laser desorption Ionization-Time of flight mass spectrometry for identification of Mycobacterium species, nocardia species, and other aerobic actinomycetes. J Clin Microbiol. 2016;54(2):376–384.
- Hall L, Doerr KA, Wohlfiel SL, et al. Evaluation of the MicroSeq system for identification of mycobacteria by 16S ribosomal DNA sequencing and its integration into a routine clinical mycobacteriology laboratory. J Clin Microbiol. 2003;41(4):1447–1453.
- CLSI. Susceptibility testing of mycobacteria, nocardia spp., and other aerobic actinomycetes. 3rd ed. CLSI standard M24. Wayne (PA): Clinical and Laboratory Standards Institute; 2018.
- Tyner HL, Wilson JW. Fifteen-year clinical experience with Mycobacterium haemophilum at the Mayo clinic: a case series. J Clin Tuberc Other Mycobact Dis. 2017;8:26–32.
- Nookeu P, Angkasekwinai N, Foongladda S, et al. Clinical characteristics and treatment outcomes for patients infected with Mycobacterium haemophilum. Emerg Infect Dis. 2019;25(9):1648–1652.
- Woodworth MH, Marquez C, Chambers H, et al. Disabling dactylitis and tenosynovitis due to Mycobacterium haemophilum in a patient with human immunodeficiency virus/acquired immune deficiency syndrome. Open Forum Infect Dis. 2017;4(3):ofx165.
- Eyer-Silva WA, Almeida MR, Martins CJ, et al. Antiretroviral therapy-induced paradoxical worsening of previously healed Mycobacterium haemophilum cutaneous lesions in advanced HIV infection. Rev Inst Med Trop Sao Paulo. 2019;61:e71.
- Jacobs SE, Zhong E, Hartono C, et al. The brief case: disseminated Mycobacterium haemophilum infection in a kidney transplant recipient. J Clin Microbiol. 2018;56(1):e00561–17. t
- Cross GB, Le Q, Webb B, et al. Mycobacterium haemophilum bone and joint infection in HIV/AIDS: case report and literature review. Int J STD AIDS. 2015;26(13):974–981.
- Kelley CF, Armstrong WS, Eaton ME. Disseminated Mycobacterium haemophilum infection. Lancet Infect Dis. 2011;11(7):571–578.
- Males BM, West TE, Bartholomew WR. Mycobacterium haemophilum infection in a patient with acquired immune deficiency syndrome. J Clin Microbiol. 1987;25(1):186–190.
- Kon S, Franco-Paredes C, Hawkins KL. Intramedullary spinal cord lesions in an immunocompromised host due to Mycobacterium haemophilum. IDCases. 2020;19:e00674.
- Ross NA, Osley KL, Sahu J, et al. Mycobacterium haemophilum: a challenging treatment dilemma in an immunocompromised patient. Cutis. 2019;104(3):E7–e10.
- Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis. 2005;5(6):361–373.
- Tønjum T, Welty DB, Jantzen E, et al. Differentiation of Mycobacterium ulcerans, M. marinum, and M. haemophilum: mapping of their relationships to M. tuberculosis by fatty acid profile analysis, DNA-DNA hybridization, and 16S rRNA gene sequence analysis. J Clin Microbiol. 1998;36(4):918–925.
- Spencer JS, Brennan PJ. The role of Mycobacterium leprae phenolic glycolipid I (PGL-I) in serodiagnosis and in the pathogenesis of leprosy. Lepr Rev. 2011;82(4):344–357.
- Hsu DC, Faldetta KF, Pei L, et al. A paradoxical treatment for a paradoxical condition: infliximab use in three cases of mycobacterial IRIS. Clin Infect Dis. 2016;62(2):258–261.
- Cevaal PM, Bekker L-G, Hermans S. TB-IRIS pathogenesis and new strategies for intervention: insights from related inflammatory disorders. Tuberculosis (Edinb). 2019;118:101863.
- Zeharia A, Eidlitz-Markus T, Haimi-Cohen Y, et al. Management of nontuberculous Mycobacteria-Induced cervical lymphadenitis with observation alone. Pediatr Infect Dis J. 2008;27(10):920–922.